Belpointe Asset Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.46M | Buy |
5,014
+144
| +3% | +$78.1K | 0.09% | 204 |
|
|
2025
Q4 | $2.82M | Buy |
4,870
+278
| +6% | +$157K | 0.1% | 170 |
|
|
2025
Q3 | $2.23M | Sell |
4,592
-684
| -13% | -$318K | 0.09% | 205 |
|
|
2025
Q2 | $2.14M | Sell |
5,276
-551
| -9% | -$230K | 0.09% | 196 |
|
|
2025
Q1 | $2.9M | Sell |
5,827
-426
| -7% | -$231K | 0.15% | 129 |
|
|
2024
Q4 | $3.85M | Sell |
6,253
-25
| -0.4% | -$13.7K | 0.23% | 86 |
|
|
2024
Q3 | $3.88M | Buy |
6,278
+13
| +0.2% | +$7.7K | 0.23% | 84 |
|
|
2024
Q2 | $3.46M | Sell |
6,265
-109
| -2% | -$62.4K | 0.24% | 77 |
|
|
2024
Q1 | $3.7M | Buy |
6,374
+352
| +6% | +$198K | 0.28% | 69 |
|
|
2023
Q4 | $3.2M | Buy |
6,022
+1,407
| +30% | +$681K | 0.28% | 65 |
|
|
2023
Q3 | $2.34M | Buy |
4,615
+13
| +0.3% | +$6.93K | 0.24% | 77 |
|
|
2023
Q2 | $2.4M | Sell |
4,602
-1,792
| -28% | -$967K | 0.25% | 82 |
|
|
2023
Q1 | $3.68M | Buy |
6,394
+238
| +4% | +$134K | 0.2% | 97 |
|
|
2022
Q4 | $3.39M | Buy |
6,156
+394
| +7% | +$209K | 0.2% | 93 |
|
|
2022
Q3 | $2.92M | Buy |
5,762
+552
| +11% | +$309K | 0.2% | 98 |
|
|
2022
Q2 | $2.83M | Sell |
5,210
-1,105
| -17% | -$608K | 0.19% | 112 |
|
|
2022
Q1 | $3.73M | Sell |
6,315
-532
| -8% | -$306K | 0.23% | 80 |
|
|
2021
Q4 | $4.57M | Sell |
6,847
-352
| -5% | -$220K | 0.28% | 73 |
|
|
2021
Q3 | $4.11M | Buy |
7,199
+1,850
| +35% | +$1.02M | 0.28% | 69 |
|
|
2021
Q2 | $2.7M | Buy |
5,349
+880
| +20% | +$415K | 0.19% | 109 |
|
|
2021
Q1 | $2.04M | Sell |
4,469
-1,348
| -23% | -$643K | 0.17% | 123 |
|
|
2020
Q4 | $2.71M | Buy |
5,817
+361
| +7% | +$169K | 0.24% | 86 |
|
|
2020
Q3 | $2.41M | Buy |
5,456
+1,089
| +25% | +$450K | 0.27% | 81 |
|
|
2020
Q2 | $1.58M | Sell |
4,367
-134
| -3% | -$44.9K | 0.2% | 105 |
|
|
2020
Q1 | $1.28M | Sell |
4,501
-209
| -4% | -$65.9K | 0.22% | 105 |
|
|
2019
Q4 | $1.53M | Buy |
4,710
+2,882
| +158% | +$874K | 0.19% | 122 |
|
|
2019
Q3 | $533K | Buy |
1,828
+264
| +17% | +$75.6K | 0.09% | 263 |
|
|
2019
Q2 | $459K | Sell |
1,564
-2,672
| -63% | -$736K | 0.09% | 245 |
|
|
2019
Q1 | $1.16M | Buy |
4,236
+2,740
| +183% | +$682K | 0.23% | 75 |
|
|
2018
Q4 | $335K | Sell |
1,496
-1,150
| -43% | -$270K | 0.08% | 259 |
|
|
2018
Q3 | $646K | Sell |
2,646
-279
| -10% | -$64.2K | 0.1% | 198 |
|
|
2018
Q2 | $606K | Buy |
+2,925
| New | +$621K | 0.17% | 120 |
|
|
2018
Q1 | – | Sell |
-1,963
| Closed | -$373K | – | 472 |
|
|
2017
Q4 | $373K | Buy |
1,963
+492
| +33% | +$94.3K | 0.08% | 294 |
|
|
2017
Q3 | $278K | Buy |
+1,471
| New | +$266K | 0.07% | 331 |
|
Other funds holding TMO
VCM
Belpointe Asset Management's TMO Position: Q1 2026 in Review
Belpointe Asset Management increased its Thermo Fisher Scientific (TMO) stake by 3% in Q1 2026, buying an estimated $78.1K and bringing the position to 5,014 shares worth $2.46M. The position accounts for 0.09% of the portfolio, ranked #204.
Belpointe Asset Management first reported a position in TMO in Q3 2017 and has held it in 34 quarters since. The position peaked at $4.57M in Q4 2021. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Belpointe Asset Management held 5,014 shares of Thermo Fisher Scientific worth $2.46M as of Q1 2026.
- Belpointe Asset Management bought 144 Thermo Fisher Scientific shares in Q1 2026, an estimated $78.1K.
- Thermo Fisher Scientific made up 0.09% of Belpointe Asset Management's portfolio in Q1 2026, its #204 holding.
- Belpointe Asset Management first reported a position in Thermo Fisher Scientific in Q3 2017 and has held it in 34 quarters since.
- Belpointe Asset Management's Thermo Fisher Scientific position peaked at $4.57M in Q4 2021.
- 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Belpointe Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.